NEWS & MEDIA
October 28, 2021
ACTUATE THERAPEUTICS ANNOUNCES PRIMARY ENDPOINT MET IN PHASE 2 STUDY IN PANCREATIC CANCER
August 4, 2021
ACTUATE THERAPEUTICS ANNOUNCES FDA FAST TRACK DESIGNATION FOR 9-ING-41 FOR TREATMENT OF PANCREATIC CANCER
July 31, 2020
ACTUATE THERAPEUTICS ANNOUNCES INITIATION OF PHASE 2 CLINICAL STUDY IN PANCREATIC CANCER
PARTNERING
As we continue to develop novel therapies to improve outcomes for patients. We are open to new partnerships with academic and scientific organizations.